BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 22, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Adcetris brentuximab vedotin regulatory update

FDA granted accelerated approval to a pair of BLAs from Seattle Genetics for Adcetris to treat Hodgkin's lymphoma and anaplastic large cell lymphoma (ALCL). FDA, which approved Adcetris ahead of its Aug. 30 PDUFA date, said the drug is the first new approved treatment for Hodgkin's lymphoma since 1977 and the first specifically indicated for ALCL. Seattle Genetics said it will launch the product this week. The company plans to discuss the...

Read the full 338 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >